


## ALX-1393

<b>Cat. No.:</b>	HY-111029		
<b>CAS No.:</b>	949164-09-4		
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>22</sub> FNO <sub>4</sub>		
<b>Molecular Weight:</b>	395.42		
<b>Target:</b>	GlyT		
<b>Pathway:</b>	Membrane Transporter/Ion Channel; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	ALX-1393, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	GlyT2
<b>In Vivo</b>	ALX1393 (i.c.v.; 25, 50, and 100 µg) in normal rats suppresses the late-phase response in the formalin test but does not affect motor performance. ALX1393 inhibits mechanical and cold hyperalgesia in a dose-dependent manner <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Haranishi Y, et al. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. *Anesth Analg*. 2010 Feb 1;110(2):615-21.
- [2]. Takahashi Y, et al. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. *Pharmacol Biochem Behav*. 2015 Mar;130:46-52.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA